Adiposopathy: Treating pathogenic adipose tissue to reduce cardiovascular disease risk

被引：21

作者：

Bays H. ^{[1
]}

Rodbard H.W. ^{[1
]}

Schorr A.B. ^{[1
]}

González-Campoy J.M. ^{[1
]}

机构：

[1] L-MARC Research Center, Louisville, KY 40213

来源：

Current Treatment Options in Cardiovascular Medicine | 2007年 / 9卷 / 4期

关键词：

Pioglitazone; Orlistat; Rimonabant; Main Drug Interaction; Sibutramine;

D O I：

10.1007/s11936-007-0021-6

中图分类号：

学科分类号：

摘要：

Excessive adipose tissue is potentially pathogenic due to its mass effects and through adverse metabolic/immune responses, which may lead to cardiovascular disease risk factors (eg, type 2 diabetes mellitus, hypertension, dyslipidemia, and possibly atherosclerosis itself). Positive caloric balance in genetically/environmentally susceptible patients may result in adipocyte hypertrophy, visceral adipose tissue accumulation, and ectopic fat deposition, all causally associated with metabolic disease, and all anatomic manifestations of "adiposopathy" (a term used to describe adipose tissue pathology). Weight loss through improved nutrition, increased physical activity, and weight loss agents (ie, orlistat and sibutramine) improves adiposopathy and improves many metabolic diseases whose prevalence are directly associated with an increase in body fat and sedentary lifestyle. Cannabinoid receptor antagonists improve adiposopathy through weight reduction and favorable metabolic effects upon multiple body organs (including adipocytes). Peroxisome proliferator-activated receptor-γ agonists may improve adiposopathy through recruitment of functional fat cells and apoptosis of dysfunctional fat cells. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：259 / 271

页数：12

共 57 条

[1] Bays H., Ballantyne C., Adiposopathy: Why do adiposity and obesity cause metabolic disease?, Future Lipidol, 1, pp. 389-420, (2006)
[2] Global Strategy on Diet, Physical Activity and Health
[3] Bays H., Chapman R., Grandy S., The relationship of body mass index to diabetes mellitus, hypertension, and dyslipidemia: Comparison of data of two national surveys, Int J Clin Pract, 61, pp. 737-747, (2007)
[4] Bays H., Abate N., Chandalia M., Adiposopathy: Sick fat causes high blood sugar, high blood pressure, and dyslipidemia, Future Cardiol, 1, pp. 39-59, (2005)
[5] Bays H., Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything, Expert Rev Cardiovasc Ther, 3, pp. 393-404, (2005)
[6] Bays H., Blonde L., Rosenson R., Adiposopathy: How do diet, exercise, weight loss and drug therapies improve metabolic disease?, Expert Rev Cardiovasc Ther, 4, pp. 871-895, (2006)
[7] Bays H.E., Current and investigational antiobesity agents and obesity therapeutic treatment targets, Obes Res, 12, pp. 1197-1211, (2004)
[8] Bays H., Adiposopathy: Defining, diagnosing, and establishing indications to treat "sick fat": what are the regulatory considerations?, US Endocrine Disease, 2, pp. 12-14, (2006)
[9] Bays H., Dujovne C.A., Adiposopathy is a more rational treatment target for metabolic disease than obesity alone, Curr Atheroscler Rep, 8, pp. 144-156, (2006)
[10] Kershaw E.E., Flier J.S., Adipose tissue as an endocrine organ, J Clin Endocrinol Metab, 89, pp. 2548-2556, (2004)

← 1 2 3 4 5 6 →